Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Bristol-Myers Squibb (NY: BMY)
61.33 USD  +0.44 (+0.72%)
Official Closing Price  /  Updated: 7:59 PM EDT, Jun 5, 2020  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 11,862,500
Open 61.18
Bid (Size) 61.30 (5)
Ask (Size) 61.40 (17)
Prev. Close 60.89
Today's Range 60.53 - 61.77
52wk Range 42.48 - 68.34
Shares Outstanding 1,634,538,458
Dividend Yield 2.61%
Performance
YTD
-3.17%
-3.17%
1 Month
+0.48%
+0.48%
3 Month
+9.23%
+9.23%
6 Month
+0.08%
+0.08%
1 Year
+31.19%
+31.19%
Top News
More News
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bristol-Myers Squibb Company - BMY.RT
from GlobeNewswire News Releases
Cullinan Oncology Completes $98.5 Million Series B Financing
Cullinan Oncology Raises $98.5M Series B, Names Chief Medical Officer, to Advance Clinical Oncology Programs Read More
from Business Wire News Releases
More News
Read More
Bristol Myers Squibb to Take Part in 41st Annual Goldman Sachs Global Healthcare Conference
from Business Wire News Releases
New Data Reinforce Improved and Durable Clinical Responses of Orencia in Moderate-to-Severe Early Rheumatoid Arthritis Patients with Autoantibodies Linked to More Severe Disease
from Business Wire News Releases
S&P 500 Analyst Moves: BMY
category Stocks
from Market News Video
Bristol-Myers Squibb Achieves #148 Analyst Rank, Surpassing Ball
category ETFs
from ETF Channel
Bristol Myers Squibb Announces Positive Topline Results from Pivotal Phase 3 True North Trial Evaluating Zeposia (ozanimod) in Patients with Moderate to Severe Ulcerative Colitis
from Business Wire News Releases
Bristol Myers Squibb Announces Commercial Launch and Availability of ZEPOSIA® (ozanimod), a New Oral Treatment for Relapsing Forms of Multiple Sclerosis
from Business Wire News Releases
3 Top Biotech Stocks to Buy in June
category CRSP , VRTX , ICPT , and 3 more.
from Motley Fool
3 Dirt-Cheap Stocks You Simply Shouldn't Ignore
category BRK/A , Market News , BRK/B , and 2 more.
from Motley Fool
Traders Share Their Health Care Picks
category CNBC , General , Media , and 8 more.
from Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.